Mister Spex SE : The re-acceleration in growth is reassuring but the context remains difficult

>Q3 revenue up +18% of which +16% for prescription sales, limited EBITDA loss, full-year guidance reiterated - The group has published Q3 revenue of € 58.3m, i.e. y-o-y growth of +18% (after +8% in H1) and adjusted EBITDA for the quarter of -€ 0.6m (margin of -1.0% vs 0.5% a year earlier, in H1 adjusted EBITDA was -€ 4m, i.e. a margin of -3.7%). We were forecasting, respectively, € 55.8m (+13% y-o-y) and -€ 3.0m (margin of -5.4%). The group, buoyed by growth of +36% i...